Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene
- PMID: 21644
- DOI: 10.1007/BF00346479
Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene
Abstract
Psychotic women with schizophrenic symptoms were treated with melperone 100 mg X 3 (n = 29) or thiothixene 10 mg X 3 (N = 34) USING A DOUBLE-BLIND PROCEDURE. Before and during treatment, levels of HVA, MOPEG, and 5-HIAA, the major metabolites of DA, NE, and 5-HT, were determined in lumbar cerebrospinal fluid by a mass fragmentographic technique. Both treatments resulted in an elevation of the HVA levels after 2 weeks, thiothixene having a more marked effect. The effect of thiothixene but not of melperone persisted after 4 weeks. Thiothixene did not influence the MOPEG level, but melperone reduced it after 4 weeks of treatment. The 5-HIAA levels were not significantly altered by the drugs. The HVA/MOPEG and the HVA/5-HIAA ratios were highly significantly elevated by both drugs after 2 as well as 4 weeks. Thiothixene induced a significantly greater change of these ratios than melperone. The results supply evidence that thiothixene accelerates central dopamine metabolism in man, presumably by blocking DA receptors. Melperone appears to act similarly, but has an effect which is weaker and/or of shorter duration. During long-term treatment with melperone the receptors develop tolerance to it. The acceleration in DA metabolism declines and the effect of melperone switches instead to central NA metabolism. The results indicate that both drugs cause long-term changes in the activity ratios of central monoamine systems. It is suggested that such changes in several systems rather than single biochemical events may be related to the antipsychotic effects of neuroleptic drugs. This study also demonstrated the versatility of using monoamine metabolite analysis of the CSF as a tool for the quantification of biochemical effects of neuroleptic drugs on the human CNS.
Similar articles
-
Melperone in the treatment of schizophrenia.Acta Psychiatr Scand Suppl. 1989;352:35-9. doi: 10.1111/j.1600-0447.1989.tb06434.x. Acta Psychiatr Scand Suppl. 1989. PMID: 2479227 Clinical Trial.
-
Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women.Arch Psychiatr Nervenkr (1970). 1979;227(3):181-92. doi: 10.1007/BF00367389. Arch Psychiatr Nervenkr (1970). 1979. PMID: 94992 No abstract available.
-
Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.Prog Biochem Pharmacol. 1980;16:133-40. Prog Biochem Pharmacol. 1980. PMID: 6160594
-
Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?Med Biol. 1985;63(1):1-17. Med Biol. 1985. PMID: 2582215 Review.
-
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.Brain Res. 1974 Oct 11;79(1):1-8. doi: 10.1016/0006-8993(74)90562-9. Brain Res. 1974. PMID: 4279131 Review. No abstract available.
Cited by
-
Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4. doi: 10.1007/BF00496052. Psychopharmacology (Berl). 1979. PMID: 115032
-
Clinical investigation of monoamine neurotransmitter interactions.Psychopharmacology (Berl). 1993;112(1 Suppl):S76-84. doi: 10.1007/BF02245010. Psychopharmacology (Berl). 1993. PMID: 7831444 Review.
-
Effect of sulpiride on monoaminergic mechanisms in psychotic women.Psychopharmacology (Berl). 1979 Aug 8;64(2):135-9. doi: 10.1007/BF00496053. Psychopharmacology (Berl). 1979. PMID: 115033
-
Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.Brain Res. 2019 Nov 15;1723:146398. doi: 10.1016/j.brainres.2019.146398. Epub 2019 Aug 21. Brain Res. 2019. PMID: 31442412 Free PMC article. Review.
-
Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.J Neural Transm. 1983;57(1-2):103-10. doi: 10.1007/BF01250052. J Neural Transm. 1983. PMID: 6194254